Atorvastatin production process
Pro Research Analysisby 
Searched over 200M research papers
Biocatalytic and Enzymatic Processes for Atorvastatin Production
Recent advances in atorvastatin production have focused on green, efficient, and highly selective biocatalytic processes. One notable method uses a two-step, three-enzyme system to synthesize a key intermediate. The first step involves the biocatalytic reduction of ethyl-4-chloroacetoacetate using a ketoreductase (KRED) with glucose and a NADP-dependent glucose dehydrogenase (GDH) for cofactor regeneration, yielding (S) ethyl-4-chloro-3-hydroxybutyrate with high yield and enantiomeric excess. The second step employs a halohydrin dehalogenase (HHDH) to replace the chloro group with a cyano group, significantly improving productivity through enzyme evolution. This process is both economical and environmentally friendly, with a low E factor, indicating minimal waste generation .
Another innovative approach uses a multi-enzyme route for producing the atorvastatin side-chain. This method features a double aldol addition catalyzed by 2-deoxyribose-5-phosphate aldolase (DERA), followed by oxidation, lipase-catalyzed acylation, and deprotection steps. The process can be optimized using mathematical modeling and can be performed in a one-pot, sequential manner, enhancing productivity and process efficiency . Similarly, a scalable aldolase-catalyzed process has been developed for the enantioselective synthesis of statin intermediates, achieving high productivity and selectivity by optimizing enzyme activity and reaction conditions .
Chemical Synthesis and Process Optimization
Traditional chemical synthesis routes for atorvastatin involve multiple steps, including the reaction of alkyl aldehyde compounds with diazo acetates to form beta-keto esters, followed by deprotection, reduction, and lactonization to yield atorvastatin. These methods emphasize economic viability and stereoselectivity . Another process involves the reaction of cis-t-butyl-6-substituted-3,5-dihydroxy-hexanoate with trialkylortho formate, reduction, N-alkylation, and final deprotection and hydrolysis, aiming to minimize by-products and improve yield and purity under mild conditions .
Process optimization studies have also been conducted using orthogonal experimental design to determine the best conditions for synthesizing atorvastatin intermediates. Factors such as temperature, material ratios, solvent addition, and reaction time are systematically varied to maximize yield, with optimal conditions resulting in yields of about 57% to 61% . Additional improvements in yield and purity are achieved by using zeolite molecular sieves as catalysts and recycling excess reactants .
Continuous Manufacturing and Crystallization Techniques
Continuous manufacturing is emerging as a promising approach for atorvastatin calcium production. An integrated, modular system combines reaction, crystallization, spherical agglomeration, filtration, and drying in a continuous process. This method enhances control over process parameters, improves product quality, and increases manufacturing efficiency. Key process variables, such as filtration and drying times, are optimized to maximize yield and throughput, demonstrating the potential for intensified, integrated pharmaceutical manufacturing .
Continuous crystallization using oscillatory baffled crystallizers (COBC) has also been explored to address challenges in batch crystallization, such as low productivity and wide crystal size distribution. The COBC allows for better control of supersaturation and temperature, resulting in a 30-fold increase in productivity and significantly reduced cycle times. The process also produces crystals with a narrower size distribution and improved polymorphic purity .
Specialized Synthesis for Research Applications
For research purposes, specialized synthesis methods have been developed, such as the production of [18F]atorvastatin for molecular imaging. This involves a ruthenium-mediated late-stage 18F-deoxyfluorination, optimized for practical use and automation. The resulting compound is stable in serum and can be used to study statin mechanisms and biodistribution in vivo .
Conclusion
The production process for atorvastatin has evolved significantly, with advances in biocatalytic, enzymatic, and chemical synthesis methods improving efficiency, selectivity, and environmental sustainability. Continuous manufacturing and advanced crystallization techniques further enhance productivity and product quality. These innovations collectively support the scalable, economical, and high-purity production of atorvastatin for pharmaceutical use K.2009Svarc2020송윤석2007+7 MORE.
Sources and full results
Most relevant research papers on this topic